Gregory Vonmering, MD
Interventional Cardiology · Ocala, FLNPI 1730193335
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Edwards Lifesciences at 49.4% of the total. 2025 is the largest year on record at $36,463, 4.9 times the $7,462 reported in 2019. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $235.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$30K
- Abbott$14K
- Boston Scientific$11K
- Medtronic$4K
- Abiomed$660
- Inari Medical, Inc.$238
- plus $1K from 14 others
Across 52 payments — averaging $3415.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$95K
- Abbott$60K
- W. L. Gore & Associates, Inc.$20K
- Abiomed$3K
What the payments were for
- Consulting fees$27,77546%
- Speaking & faculty fees$8,60014%
- Travel & lodging$13,25022%
- Food & beverage$11,19018%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 43 | $30,027 |
| Abbott | 77 | $13,766 |
| Boston Scientific | 28 | $10,769 |
| Medtronic(2 entities) | 59 | $4,097 |
| Abiomed | 7 | $660 |
| Inari Medical, Inc. | 4 | $238 |
| Cardiva Medical, Inc. | 3 | $237 |
| Shockwave Medical, Inc | 2 | $177 |
| W. L. Gore & Associates, Inc. | 2 | $164 |
| Philips North America LLC | 6 | $138 |
| Penumbra, Inc. | 8 | $115 |
| Corindus Inc. | 1 | $88 |
| Novartis | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $53 |
| Amgen | 2 | $37 |
| Teleflex LLC | 2 | $34 |
| Siemens Medical Solutions USA, Inc. | 1 | $30 |
| Cvrx, Inc. | 1 | $24 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$25,110
- NAVITOR$7,767
- GENERAL - THERAPIES$3,906
- Watchman$3,227
- GENERAL VASCULAR INTERVENTION$3,000
- SAPIEN 3 Ultra RESILIA$2,878
- Mitra Clip system$1,578
- TRICLIP$1,521
- COREVALVE EVOLUT R$1,256
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$949
- CoreValve Evolut$876
- MitraClip$856
- Impella$455
- THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM$359
- Micra$204
- Cardiovascular- Research only$189
- PORTICO$164
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$157
- ONYX FRONTIER$129
- CARDIOFORM Septal Occluder$126
How this compares
$60,814 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 39 | $46,082 |
| EliquisApixaban | 28 | $32,445 |
| BrilintaTicagrelor | 36 | $18,272 |
| ClopidogrelClopidogrel Bisulfate | 271 | $2,437 |
| Metoprolol Succinate | 56 | $621 |
| Losartan Potassium | 37 | $299 |
| Potassium Chloride | 21 | $205 |
| Carvedilol | 17 | $109 |
| Rosuvastatin Calcium | 12 | $103 |
| Atorvastatin Calcium | 15 | $99 |
| Metoprolol Tartrate | 20 | $88 |
| Furosemide | 30 | $86 |
| Prednisone | 20 | $18 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $82 | $46,08239 claims |
| AstraZenecaBrilinta | $18 | $18,27236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Ocala
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.